CLNN - Clene down 33% as FDA denies accelerated approval for ALS therapy
2023-12-21 09:06:53 ET
More on Clene
- Clene gains after $45M federal grant to study lead asset in ALS
- Seeking Alpha’s Quant Rating on Clene
- Historical earnings data for Clene
- Financial information for Clene
For further details see:
Clene down 33% as FDA denies accelerated approval for ALS therapy